Zobrazeno 1 - 10 of 93 pro vyhledávání: '"Alffenaar, J.W.C"'
2
Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial
Autor: Veringa, A., Bruggemann, R.J., Span, L.F.R., Biemond, B.J., Boer, M.G.J. de, Heuvel, E.R. van den, Klein, S.K., Kraemer, D., Minnema, M.C., Prakken, N.H.J., Rijnders, B.J.A., Swen, J.J., Verweij, P.E., Wondergem, M.J., Ypma, P.F., Blijlevens, N., Kosterink, J.G.W., Werf, T.S. van der, Alffenaar, J.W.C., Voriconazole ZonMw Study Grp
Publikováno v: Voriconazole ZonMw Study Group 2023, ' Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients : a multicentre, prospective, cluster randomised, crossover clinical trial ', International Journal of Antimicrobial Agents, vol. 61, no. 2, 106711 . https://doi.org/10.1016/j.ijantimicag.2023.106711
International Journal of Antimicrobial Agents, 61(2):106711. Elsevier
International Journal of Antimicrobial Agents, 61
International journal of antimicrobial agents, 61(2):106711. Elsevier Bedrijfsinformatie b.v.
International Journal of Antimicrobial Agents, 61, 2
International Journal of Antimicrobial Agents, 61(2). ELSEVIER
International journal of antimicrobial agents, 61(2):106711. Elsevier
Objectives: Voriconazole therapeutic drug monitoring (TDM) is recommended based on retrospective data and limited prospective studies. This study aimed to investigate whether TDM-guided voriconazole treat-ment is superior to standard treatment for in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::026cba82766afd727feb5ea068df3ecb
https://hdl.handle.net/1887/3594488
Zobrazit plný text záznamu
3
Clinical standards for the management of adverse effects during treatment for TB
Autor: Singh, K.P., Carvalho, A.C.C., Centis, R., Ambrosio, L.D., Migliori, G.B., Mpagama, S.G., Nguyen, B.C., Aarnoutse, R.E., Aleksa, A., Altena, R. van, Bhavani, P.K., Bolhuis, M.S., Borisov, S., Boveneind-Vrubleuskaya, N. Van't, Bruchfeld, J., Caminero, J.A., Carvalho, I., Cho, J.G., Davies Forsman, L., Dedicoat, M., Dheda, K., Dooley, K., Furin, J., García-García, J.M., Garcia-Prats, A., Hesseling, A.C., Heysell, S.K., Hu, Y., Kim, H.Y., Manga, S., Marais, B.J., Margineanu, I., Märtson, A.G., Munoz Torrico, M., Nataprawira, H.M., Nunes, E., Ong, C.W.M., Otto-Knapp, R., Palmero, D.J., Peloquin, C.A., Rendon, A., Rossato Silva, D., Ruslami, R., Saktiawati, A.M.I., Santoso, P., Schaaf, H.S., Seaworth, B., Simonsson, U.S.H., Singla, R., Skrahina, A., Solovic, I., Srivastava, S., Stocker, S.L., Sturkenboom, M.G.G., Svensson, E.M., Tadolini, M., Thomas, T.A., Tiberi, S., Trubiano, J., Udwadia, Z.F., Verhage, A.R., Vu, D.H., Akkerman, O.W., Alffenaar, J.W.C., Denholm, J.T.
Publikováno v: International Journal of Tuberculosis and Lung Disease, 27, 7, pp. 506-519
Contains fulltext : 294242.pdf (Publisher’s version ) (Open Access) BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the di
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1236::0d8d3e7be661c32480cedfc9a66a631a
Zobrazit plný text záznamu
7
Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants
Autor: Engbers, A.G.J., Flint, R.B., Völler, S., Reiss, I., Liem, K.D., Alffenaar, J.W.C., Tibboel, D., Simons, S., Knibbe, C.A.J., Bruggemann, R.J.
Publikováno v: Archives of Disease in Childhood, 107(4):archdischild-2021-322560, 400-406. BMJ Publishing Group
Archives of Disease in Childhood, 107, 4, pp. 400-406
Archives of Disease in Childhood, 107(4), 400-406. BMJ PUBLISHING GROUP
Archives of disease in childhood, 107(4), 400-406. BMJ PUBLISHING GROUP
Archives of Disease in Childhood, 107, 400-406
IntroductionFluconazole is an important antifungal in the prevention and treatment of invasive Candida infections in neonates, even though its use in preterm infants is still off-label. Here, we performed a population pharmacokinetic study on flucona
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::931882ae3498ce0a5c3219f3c38a645c
https://doi.org/10.1136/archdischild-2021-322560
Zobrazit plný text záznamu
9
The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis
Autor: Zhang, M, Wang, S, Wilffert, B., Tong, R., Soolingen, D. van, Hof, S. van den, Alffenaar, J.W.C.
Publikováno v: British Journal of Clinical Pharmacology, 84, 12, pp. 2747-2760
British Journal of Clinical Pharmacology, 84, 2747-2760
Contains fulltext : 200451.pdf (Publisher’s version ) (Open Access) AIMS: The aim of this study is to evaluate the potential association between N-acetyltransferase type 2 (NAT2) polymorphisms and drug-induced liver injury during anti-TB treatment
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::09697ddbf9d50010701abefbdd8420e3
https://hdl.handle.net/2066/200451
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje